- ‘Cancer-Shattering’ Method Targets Non-Coding Sequences to Eradicate Brain Tumors
- What is HIV Post-Exposure Prophylaxis (PEP)?
- Moderna Team Detects No Uptake of mRNA-LNPs in Muscles at Injection Site
- Vitamin B5 Found to Promote Cancer Growth
- Harmful Chemical D5 Found in Common Hair Care Products
- Antibiotics Unveiled as Potential Life Extenders Aiding Healthier Aging
Cancer patients treated by PD-1 inhibitor had “cytokine release syndrome” after COVID-19 vaccination
Cancer patients had “cytokine release syndrome” after COVID-19 vaccination. With the advancement of vaccination, the immune response and adverse reactions after vaccination against people with underlying diseases have also been reported.
How can patients with cancer or autoimmune diseases get the COVID-19 vaccine?
On May 25, 2021, the Francis Crick Institute in the United Kingdom reported in Nature Med that a patient with colorectal cancer who had received anti-PD-1 monotherapy for a long time had cells developed on the fifth day after being vaccinated with Pfizer’s mRNA vaccine BTN162b. Cases of factor release syndrome (CRS).
The 58-year-old male patient has been using PD-1 inhibitors for 2 years to treat colorectal cancer and his condition is stable. The last treatment was 27 days before vaccination.
No adverse reactions occurred immediately after vaccination. Diarrhea and myalgia occurred on the 3rd day, and fever (38.4°) on the 4th day.
The admission examination mainly found elevated inflammation markers, thrombocytopenia, and elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10).
The patient continued to have a fever 5 days after admission, reaching 39.8°. Considering the possibility of CRS (Grade 3), 1 mg/kg methylprednisolone was given intravenously for 3 days. The patient’s symptoms gradually improved.
This is the first diagnosis of cytokine storm after mRNA COVID-19 vaccination. Vaccination and the diagnosis of CRS are closely related in time, which indicates that cytokine storm is an adverse event after vaccination of patients receiving PD-1 inhibitors.
(source:internet, reference only)